Recent Sentinel Activity
This recent activity feed provides a list of the last 90 days of Sentinel activity across assessments, publications & presentations, projects, events, etc.
Loading...
Recent Activity | ||||
---|---|---|---|---|
https://www.sentinelinitiative.org/studies/drugs/provigil-modafinil-and-nuvigil-armodafinil-0 | Provigil (Modafinil) and Nuvigil (Armodafinil) & Congenital Cardiac Malformations | Studies | 11/17/2020 | Provigil (Modafinil) and Nuvigil (Armodafinil) & Congenital Cardiac MalformationsStudies 11/17/2020 |
https://www.sentinelinitiative.org/methods-data-tools/methods/covid-19-pregnancy-study-implementation | COVID-19 Pregnancy Study Implementation | Methods, Data, & Tools | 02/24/2021 | COVID-19 Pregnancy Study ImplementationMethods, Data, & Tools 02/24/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/adbry-tralokinumab | Assessment of ARIA Sufficiency: Adbry (tralokinumab) | Sufficiency Assessments | 04/08/2021 | Assessment of ARIA Sufficiency: Adbry (tralokinumab)Sufficiency Assessments 04/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/bylvay-odevixibat | Assessment of ARIA Sufficiency: Bylvay (odevixibat) | Sufficiency Assessments | 04/08/2021 | Assessment of ARIA Sufficiency: Bylvay (odevixibat)Sufficiency Assessments 04/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/camzyos-mavacamten | Assessment of ARIA Sufficiency: Camzyos (mavacamten) | Sufficiency Assessments | 04/08/2021 | Assessment of ARIA Sufficiency: Camzyos (mavacamten)Sufficiency Assessments 04/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/enjaymo-sutimlimab-jome | Assessment of ARIA Sufficiency: Enjaymo (sutimlimab-jome) | Sufficiency Assessments | 04/08/2021 | Assessment of ARIA Sufficiency: Enjaymo (sutimlimab-jome)Sufficiency Assessments 04/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/nextstellis-drospirenone-and-estetrol | Assessment of ARIA Sufficiency: Nextstellis (drospirenone and estetrol) | Assessments | 04/08/2021 | Assessment of ARIA Sufficiency: Nextstellis (drospirenone and estetrol)Assessments 04/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/quviviq-daridorexant | Assessment of ARIA Sufficiency: Quviviq (daridorexant) | Sufficiency Assessments | 04/08/2021 | Assessment of ARIA Sufficiency: Quviviq (daridorexant)Sufficiency Assessments 04/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/reyvow-lasmiditan | Assessment of ARIA Sufficiency: Reyvow (lasmiditan) | Sufficiency Assessments | 04/08/2021 | Assessment of ARIA Sufficiency: Reyvow (lasmiditan)Sufficiency Assessments 04/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/voquezna-dual-pak | Assessment of ARIA Sufficiency: Voquezna Dual Pak (vonoprazan/amoxicillin) | Sufficiency Assessments | 04/08/2021 | Assessment of ARIA Sufficiency: Voquezna Dual Pak (vonoprazan/amoxicillin)Sufficiency Assessments 04/08/2021 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/angioedema-following-sacubitrilvalsartan-use-patients-heart | Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis | Modular Programs | 04/21/2021 | Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score AnalysisModular Programs 04/21/2021 |
https://www.sentinelinitiative.org/methods-data-tools/health-outcomes-interest/angioedema-and-serious-angioedema-algorithms-defined | Angioedema and Serious Angioedema Algorithms Defined in "Angioedema following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis" | Methods, Data, & Tools | 04/21/2021 | Angioedema and Serious Angioedema Algorithms Defined in "Angioedema following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis"Methods, Data, & Tools 04/21/2021 |
https://www.sentinelinitiative.org/methods-data-tools/methods/extending-machine-learning-methods-development-sentinel-follow-analyses | Extending Machine Learning Methods Development in Sentinel: Follow-up Analyses for Anaphylaxis Algorithm and Formalization of a General Phenotyping Framework (Phase 3) | Methods, Data, & Tools | 05/17/2021 | Extending Machine Learning Methods Development in Sentinel: Follow-up Analyses for Anaphylaxis Algorithm and Formalization of a General Phenotyping Framework (Phase 3)Methods, Data, & Tools 05/17/2021 |
https://www.sentinelinitiative.org/methods-data-tools/methods/longitudinal-trends-incident-and-prevalent-use-long-acting-beta-2 | Longitudinal Trends in Incident and Prevalent use of Long-Acting Beta-2 Agonists: An Interrupted Time Series Analysis | Methods, Data, & Tools | 08/24/2021 | Longitudinal Trends in Incident and Prevalent use of Long-Acting Beta-2 Agonists: An Interrupted Time Series AnalysisMethods, Data, & Tools 08/24/2021 |
https://www.sentinelinitiative.org/news-events/publications-presentations/new-analytic-tool-interrupted-times-series-analysis-assess | A New Analytic Tool for Interrupted Times Series Analysis to Assess the Impact of FDA Regulatory Actions | Publications and Presentations | 08/24/2021 | A New Analytic Tool for Interrupted Times Series Analysis to Assess the Impact of FDA Regulatory ActionsPublications and Presentations 08/24/2021 |
https://www.sentinelinitiative.org/news-events/publications-presentations/improving-methods-identifying-anaphylaxis-medical-product | Improving Methods of Identifying Anaphylaxis for Medical Product Safety Surveillance Using Natural Language Processing and Machine Learning | Publications and Presentations | 08/25/2021 | Improving Methods of Identifying Anaphylaxis for Medical Product Safety Surveillance Using Natural Language Processing and Machine LearningPublications and Presentations 08/25/2021 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/ubrelvy-ubrogepant | Assessment of ARIA Sufficiency: Ubrelvy (ubrogepant) | Sufficiency Assessments | 08/27/2021 | Assessment of ARIA Sufficiency: Ubrelvy (ubrogepant)Sufficiency Assessments 08/27/2021 |
https://www.sentinelinitiative.org/methods-data-tools/methods/making-medicaid-data-more-accessible-through-common-data-models-and-fhir | Making Medicaid Data More Accessible Through Common Data Models and FHIR APIs | Methods, Data, & Tools | 09/24/2021 | Making Medicaid Data More Accessible Through Common Data Models and FHIR APIsMethods, Data, & Tools 09/24/2021 |
https://www.sentinelinitiative.org/news-events/publications-presentations/natural-history-coagulopathy-covid-19-0 | Natural History of Coagulopathy in COVID-19 | Publications and Presentations | 10/06/2021 | Natural History of Coagulopathy in COVID-19Publications and Presentations 10/06/2021 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2022-sentinel-community-building-and-outreach-center | 2022 Sentinel Community Building and Outreach Center Webinar Series | Sentinel Initiative Events | 11/23/2021 | 2022 Sentinel Community Building and Outreach Center Webinar SeriesSentinel Initiative Events 11/23/2021 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2022-sentinel-innovation-and-methods-seminar-series | 2022 Sentinel Innovation and Methods Seminar Series | Sentinel Initiative Events | 01/01/2022 | 2022 Sentinel Innovation and Methods Seminar SeriesSentinel Initiative Events 01/01/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/mometasone-furoate-sinus-implant-use-patients-nasal-polyps | Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis | Analyses | 03/03/2022 | Mometasone Furoate Sinus Implant Use in Patients with Nasal Polyps: A Descriptive AnalysisAnalyses 03/03/2022 |
https://www.sentinelinitiative.org/engage-sentinel/quarterly-newsletter | Quarterly Newsletter | Spotlight | 03/24/2022 | Quarterly NewsletterSpotlight 03/24/2022 |
https://www.sentinelinitiative.org/methods-data-tools/methods/approaches-handling-partially-observed-confounder-data-electronic-health | Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication Outcomes | Methods, Data, & Tools | 06/01/2022 | Approaches to Handling Partially Observed Confounder Data From Electronic Health Records (EHR) In Non-randomized Studies of Medication OutcomesMethods, Data, & Tools 06/01/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-sodium-glucose-co-transporter-2-sglt-2-inhibitor | Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive Analysis | Analyses | 07/11/2022 | Utilization of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitor Drugs: A Descriptive AnalysisAnalyses 07/11/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-obesity-drugs-descriptive-analysis | Utilization of Obesity Drugs: A Descriptive Analysis | Analyses | 08/05/2022 | Utilization of Obesity Drugs: A Descriptive AnalysisAnalyses 08/05/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/association-covid-19-vs-influenza-risk-arterial-and-venous | Association of COVID-19 vs Influenza with Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients | Publications and Presentations | 08/16/2022 | Association of COVID-19 vs Influenza with Risk of Arterial and Venous Thrombotic Events Among Hospitalized PatientsPublications and Presentations 08/16/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/impact-nitrosamine-contamination-recalls-angiotensin | Impact of Nitrosamine Contamination Recalls on Angiotensin-Receptor-Blocker (ARB) Utilization in the U.S., U.K., Canada, and Denmark | Publications and Presentations | 08/26/2022 | Impact of Nitrosamine Contamination Recalls on Angiotensin-Receptor-Blocker (ARB) Utilization in the U.S., U.K., Canada, and DenmarkPublications and Presentations 08/26/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/racial-differences-us-covid-19-positivity-hospitalization | Racial Differences in U.S. COVID-19 Positivity, Hospitalization, and Mortality | Spotlight | 08/28/2022 | Racial Differences in U.S. COVID-19 Positivity, Hospitalization, and MortalitySpotlight 08/28/2022 |
https://www.sentinelinitiative.org/methods-data-tools/sentinel-national-resource/patient-characteristics-pain-treatment-patterns-and | Patient Characteristics, Pain Treatment Patterns, and Incidence of Total Joint Replacement in a US Population With Osteoarthritis | 09/23/2022 | Patient Characteristics, Pain Treatment Patterns, and Incidence of Total Joint Replacement in a US Population With Osteoarthritis09/23/2022 |
|
https://www.sentinelinitiative.org/news-events/publications-presentations/association-covid-19-vs-influenza-risk-arterial-and-venous-0 | Association of COVID-19 vs Influenza with Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients | Publications and Presentations | 10/20/2022 | Association of COVID-19 vs Influenza with Risk of Arterial and Venous Thrombotic Events Among Hospitalized PatientsPublications and Presentations 10/20/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/spironolactone-utilization-among-patients-reduced-and | Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure | Publications and Presentations | 10/20/2022 | Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart FailurePublications and Presentations 10/20/2022 |
https://www.sentinelinitiative.org/methods-data-tools/methods/onboarding-commercial-electronic-health-record-ehr-data-partners | Onboarding of Commercial Electronic Health Record (EHR) Data Partners | Methods, Data, & Tools | 11/01/2022 | Onboarding of Commercial Electronic Health Record (EHR) Data PartnersMethods, Data, & Tools 11/01/2022 |
https://www.sentinelinitiative.org/methods-data-tools/software-packages-toolkits/centers-medicare-and-medicaid-services-cms-medicaid | The Centers for Medicare and Medicaid Services (CMS): Medicaid and Children’s Health Insurance Program (CHIP) Claims in Sentinel Common Data Model (SCDM) Format | Methods, Data, & Tools | 11/01/2022 | The Centers for Medicare and Medicaid Services (CMS): Medicaid and Children’s Health Insurance Program (CHIP) Claims in Sentinel Common Data Model (SCDM) FormatMethods, Data, & Tools 11/01/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/new-analytic-tool-assessing-impact-us-food-and-drug | A New Analytic Tool for Assessing the Impact of the US Food and Drug Administration Regulatory Actions | Publications and Presentations | 11/04/2022 | A New Analytic Tool for Assessing the Impact of the US Food and Drug Administration Regulatory ActionsPublications and Presentations 11/04/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/improving-methods-identifying-anaphylaxis-medical-product-0 | Improving Methods of Identifying Anaphylaxis for Medical Product Safety Surveillance Using Natural Language Processing and Machine Learning | Publications and Presentations | 11/04/2022 | Improving Methods of Identifying Anaphylaxis for Medical Product Safety Surveillance Using Natural Language Processing and Machine LearningPublications and Presentations 11/04/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/data-driven-automated-classification-algorithms-acute-health | Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID 19 Disease | Publications and Presentations | 11/07/2022 | Data-Driven Automated Classification Algorithms for Acute Health Conditions: Applying PheNorm to COVID 19 DiseasePublications and Presentations 11/07/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/assessing-medical-product-safety-during-pregnancy-using | Assessing Medical Product Safety During Pregnancy using Parameterizable Tools in the Sentinel Distributed Database | Publications and Presentations | 11/09/2022 | Assessing Medical Product Safety During Pregnancy using Parameterizable Tools in the Sentinel Distributed DatabasePublications and Presentations 11/09/2022 |
https://www.sentinelinitiative.org/studies/drugs/ozempic-semaglutide | Ozempic (Semaglutide) & Signal Identification | Studies | 11/10/2022 | Ozempic (Semaglutide) & Signal IdentificationStudies 11/10/2022 |
https://www.sentinelinitiative.org/studies/drugs/zarxio-filgrastim-sndz | Zarxio (Filgrastim-sndz) & Signal Identification | Studies | 11/10/2022 | Zarxio (Filgrastim-sndz) & Signal IdentificationStudies 11/10/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-zarxio-use-signal | Outcome Monitoring Following Zarxio Use: A Signal Identification Analysis | Analyses | 11/10/2022 | Outcome Monitoring Following Zarxio Use: A Signal Identification AnalysisAnalyses 11/10/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/outcome-monitoring-following-ozempic-use-patients-type-2 | Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification Analysis | Analyses | 11/10/2022 | Outcome Monitoring Following Ozempic Use in Patients with Type 2 Diabetes: A Signal Identification AnalysisAnalyses 11/10/2022 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/utilization-ixekizumab-pregnant-patients-descriptive | Utilization of Ixekizumab in Pregnant Patients: A Descriptive Analysis | Analyses | 11/14/2022 | Utilization of Ixekizumab in Pregnant Patients: A Descriptive AnalysisAnalyses 11/14/2022 |
https://www.sentinelinitiative.org/studies/drugs/taltz-ixekizumab | Taltz (Ixekizumab) & Use in Pregnancy | Studies | 11/14/2022 | Taltz (Ixekizumab) & Use in PregnancyStudies 11/14/2022 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2022-14th-annual-sentinel-public-workshop | 2022 14th Annual Sentinel Public Workshop | Sentinel Initiative Events | 11/15/2022 | 2022 14th Annual Sentinel Public WorkshopSentinel Initiative Events 11/15/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/scalable-phenotyping-safety-outcomes-using-electronic-health | Scalable Phenotyping for Safety Outcomes Using Electronic Health Record Data | Publications and Presentations | 11/17/2022 | Scalable Phenotyping for Safety Outcomes Using Electronic Health Record DataPublications and Presentations 11/17/2022 |
https://www.sentinelinitiative.org/news-events/publications-presentations/using-food-and-drug-administrations-sentinel-system | Using the Food and Drug Administration's Sentinel System for Surveillance of TB Infection | Publications and Presentations | 12/01/2022 | Using the Food and Drug Administration's Sentinel System for Surveillance of TB InfectionPublications and Presentations 12/01/2022 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/wegovy-semaglutide | Assessment of ARIA Sufficiency: Wegovy (semaglutide) | Sufficiency Assessments | 12/07/2022 | Assessment of ARIA Sufficiency: Wegovy (semaglutide)Sufficiency Assessments 12/07/2022 |
https://www.sentinelinitiative.org/methods-data-tools/methods/inclusion-semi-structured-and-unstructured-electronic-health-record-ehr | Inclusion of Semi-Structured and Unstructured Electronic Health Record (EHR) Data in Confounding Adjustment and Outcome Ascertainment | Methods, Data, & Tools | 12/09/2022 | Inclusion of Semi-Structured and Unstructured Electronic Health Record (EHR) Data in Confounding Adjustment and Outcome AscertainmentMethods, Data, & Tools 12/09/2022 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/empaveli-pegcetacoplan | Assessment of ARIA Sufficiency: Empaveli (pegcetacoplan) | Sufficiency Assessments | 12/12/2022 | Assessment of ARIA Sufficiency: Empaveli (pegcetacoplan)Sufficiency Assessments 12/12/2022 |
https://www.sentinelinitiative.org/methods-data-tools/methods/monitoring-safety-and-effectiveness-covid-19-therapeutics-aim-1-protocol | Monitoring of Safety and Effectiveness of COVID-19 Therapeutics: Aim 1 Protocol Development | Study Protocols & Surveillance Plan | 12/13/2022 | Monitoring of Safety and Effectiveness of COVID-19 Therapeutics: Aim 1 Protocol DevelopmentStudy Protocols & Surveillance Plan 12/13/2022 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/machine-learning-distributed-data-networks-fda-sentinel | Machine Learning in Distributed Data Networks like the FDA Sentinel System: Opportunities, Challenges, and Considerations | Sentinel Initiative Events | 12/16/2022 | Machine Learning in Distributed Data Networks like the FDA Sentinel System: Opportunities, Challenges, and ConsiderationsSentinel Initiative Events 12/16/2022 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/nexviazyme-avalglucosidase-alfa | Assessment of ARIA Sufficiency: Nexviazyme (avalglucosidase alfa) | Sufficiency Assessments | 12/27/2022 | Assessment of ARIA Sufficiency: Nexviazyme (avalglucosidase alfa)Sufficiency Assessments 12/27/2022 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/pradaxa-dabigatran-etexilate | Assessment of ARIA Sufficiency: Pradaxa (dabigatran etexilate) | Sufficiency Assessments | 12/27/2022 | Assessment of ARIA Sufficiency: Pradaxa (dabigatran etexilate)Sufficiency Assessments 12/27/2022 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/cibinqo-abrocitinib | Assessment of ARIA Sufficiency: Cibinqo (abrocitinib) | Sufficiency Assessments | 12/29/2022 | Assessment of ARIA Sufficiency: Cibinqo (abrocitinib)Sufficiency Assessments 12/29/2022 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2023-sentinel-innovation-and-methods-seminar-series | 2023 Sentinel Innovation and Methods Seminar Series | Sentinel Initiative Events | 01/01/2023 | 2023 Sentinel Innovation and Methods Seminar SeriesSentinel Initiative Events 01/01/2023 |
https://www.sentinelinitiative.org/methods-data-tools/routine-querying-tools/sentinel-routine-querying-system | Sentinel Routine Querying System | Methods, Data, & Tools | 01/06/2023 | Sentinel Routine Querying SystemMethods, Data, & Tools 01/06/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/exploring-claims-based-definitions-and-characterizing | Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive Analysis | Analyses | 01/10/2023 | Exploring Claims-Based Definitions of, and Characterizing Patients with, Respiratory Failure: A Descriptive AnalysisAnalyses 01/10/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/identifying-potential-risk-factors-respiratory-failure | Identifying Potential Risk Factors for Respiratory Failure: A Descriptive Analysis | Analyses | 01/10/2023 | Identifying Potential Risk Factors for Respiratory Failure: A Descriptive AnalysisAnalyses 01/10/2023 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/amvuttra-vutrisiran | Assessment of ARIA Sufficiency: Amvuttra (vutrisiran) | Sufficiency Assessments | 01/11/2023 | Assessment of ARIA Sufficiency: Amvuttra (vutrisiran)Sufficiency Assessments 01/11/2023 |
https://www.sentinelinitiative.org/studies/drugs/individual-drug-analyses/characterization-patients-and-encounters-trinetx-live-usa | Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive Analysis | Analyses | 01/12/2023 | Characterization of Patients and Encounters in the TriNetX Live USA Network: A Descriptive AnalysisAnalyses 01/12/2023 |
https://www.sentinelinitiative.org/studies/drugs/olumiant-baricitinib | Olumiant (Baricitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, and Stroke | Studies | 01/17/2023 | Olumiant (Baricitinib) & Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, and StrokeStudies 01/17/2023 |
https://www.sentinelinitiative.org/studies/drugs/assessing-arias-ability-evaluate-safety-concern/voquezna-triple-pak | Assessment of ARIA Sufficiency: Voquezna Triple Pak (vonoprazan/amoxicillin/clarithromycin) | Sufficiency Assessments | 01/19/2023 | Assessment of ARIA Sufficiency: Voquezna Triple Pak (vonoprazan/amoxicillin/clarithromycin)Sufficiency Assessments 01/19/2023 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/identification-and-mitigation-source-mapping-issues | Identification and Mitigation of Source Mapping Issues in Structured Electronic Health Record Data | Sentinel Initiative Events | 01/23/2023 | Identification and Mitigation of Source Mapping Issues in Structured Electronic Health Record DataSentinel Initiative Events 01/23/2023 |
https://www.sentinelinitiative.org/news-events/publications-presentations/comparative-risk-angioedema-sacubitril-valsartan-versus | Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone Inhibitors | Publications and Presentations | 01/24/2023 | Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone InhibitorsPublications and Presentations 01/24/2023 |
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/ontology-driven-weak-supervision-clinical-entity | Ontology-Driven Weak Supervision for Clinical Entity Classification in Electronic Health Records | Sentinel Initiative Events | Ontology-Driven Weak Supervision for Clinical Entity Classification in Electronic Health RecordsSentinel Initiative Events 02/28/2023 |
|
https://www.sentinelinitiative.org/news-events/meetings-workshops-trainings/2023-sentinel-public-training-innovation-day-april-11-12 | 2023 Sentinel Public Training & Innovation Day, April 11-12 | Sentinel Initiative Events | 2023 Sentinel Public Training & Innovation Day, April 11-12Sentinel Initiative Events 04/11/2023 |